Technical Analysis for AVCT - Avacta Group Plc

Grade Last Price % Change Price Change
grade A 24.62 7.04% 1.62
AVCT closed up 12.2 percent on Monday, April 6, 2020, on 16.45 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Apr 21
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical AVCT trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 7.04%
20 DMA Support Bullish 7.04%
Crossed Above 200 DMA Bullish 7.04%
Pocket Pivot Bullish Swing Setup 7.04%
Volume Surge Other 7.04%
Stochastic Reached Overbought Strength 7.04%
Multiple of Ten Bullish Other 7.04%
Outside Day Range Expansion 7.04%
Wide Bands Range Expansion 7.04%
Overbought Stochastic Strength 7.04%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Biotechnology Medicine Branches Of Biology Medical Specialties Immune System Immunology Antibodies

Is AVCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 38.4
52 Week Low 12.6172
Average Volume 2,686,793
200-Day Moving Average 21.34
50-Day Moving Average 23.19
20-Day Moving Average 19.46
10-Day Moving Average 20.96
Average True Range 2.47
ADX 15.0
+DI 29.09
-DI 22.91
Chandelier Exit (Long, 3 ATRs ) 17.49
Chandelier Exit (Short, 3 ATRs ) 20.03
Upper Bollinger Band 24.93
Lower Bollinger Band 13.99
Percent B (%b) 0.82
BandWidth 56.21
MACD Line -0.18
MACD Signal Line -0.77
MACD Histogram 0.5813
Fundamentals Value
Market Cap 1.1 Billion
Num Shares 48 Million
EPS 0.00
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 3520.49
Price-to-Book 333.75
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.63
Resistance 3 (R3) 29.03 26.23 28.53
Resistance 2 (R2) 26.23 24.54 26.53 28.16
Resistance 1 (R1) 24.61 23.50 25.42 25.21 27.79
Pivot Point 21.81 21.81 22.21 22.11 21.81
Support 1 (S1) 20.19 20.12 21.00 20.79 18.21
Support 2 (S2) 17.39 19.08 17.69 17.84
Support 3 (S3) 15.77 17.39 17.48
Support 4 (S4) 16.37